0 CHECKOUT

T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

  • ID: 1537341
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

Stimulation of the T cell receptor leads to the activation of NFkB and NFAT signaling modules which play a key role in T cell receptor signaling.

There are today 355 companies plus partners developing 469 T cell receptor pathway targeting drugs in 1756 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 210 drugs. T Cell Receptor Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 242 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 236 out of the 238 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 49 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at READ MORE >

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)